KHẢO SÁT SỰ THAY ĐỔI CHỈ SỐ XƠ HOÁ GAN APRI SAU ĐẠT ĐÁP ỨNG VI RÚT BỀN VỮNG Ở BỆNH NHÂN VIÊM GAN VI RÚT C MẠN ĐƯỢC ĐIỀU TRỊ BẰNG THUỐC KHÁNG VI RÚT TRỰC TIẾP

Abstract

Objective: To investigate the effectiveness of direct-acting antiviral agents (DAA) in improving liver fibrosis based on AST to Platelet Ratio Index (APRI) after achieving sustained virological response in patients with chronic hepatitis C virus (HCV). Patients and methods: We conducted a retrospective cross-sectional study on medical records of outpatients with chronic hepatitis C virus at Hepatitis clinic, University Medical Center of Ho Chi Minh City from January 2018 to December 2019. Patients were treated with 3-month DAA regimens. Clinical and laboratory data were collected before treatment, at 3 months, 6 months and 12 months after the end of treatment. The degree of liver fibrosis was assessed based on APRI. Results: Among 184 eligible patients, 113 (61.4%) were female. The mean age of patients was 57.1 ± 13.4. There were 96/184 (52.2%) without cirrhosis. In patients without cirrhosis, APRI was changed significantly at 6 months after the end of treatment compared to baseline (0.71; 0.32; respectively, p = 0.012). There was no statistically significant difference between the 12-month APRI and 6-month APRI after the end of treatment (0.32; 0.31; respectively, p = 0.385). In cirrhotic patients, APRI decreased statistically significantly at all ranges ​at 6 months after the end of treatment compared to those at baseline (1.13; 0.41; respectively, p < 0.001). Conclusion: APRI was changed significantly in patients with HCV at 6 months after the end of DAA treatment. Therefore, patients with HCV should receive early DAA therapy to limit progression of chronic liver disease.